Skip to main content
. 2020 Feb 24;27(4):382–392. doi: 10.1097/GME.0000000000001510

FIG. 4.

FIG. 4

Severity of moderate and severe VMS per 24 hours with fezolinetant BID (A) or fezolinetant QD dosing (B), Full analysis set. F/U, follow-up; VMS, vasomotor symptoms. aBaseline is the average severity of 24-hour VMS from seven nonmissing days before day 1.